Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
LLY Eli Lilly and Co
323.350
-6.660-2.02%
Post Mkt Price
323.000
-0.350-0.11%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
-16.34% 2.74B -15.83% 2.57B 6.17% 3.91B 6.17% 3.91B
-Cash and cash equivalents
-18.54% 2.62B -18.09% 2.46B 4.41% 3.82B 4.41% 3.82B
-Short-term investments
122.27% 113.8M 122.65% 109.1M 272.31% 90.1M 272.31% 90.1M
Receivables
11.15% 7.67B 17.23% 7.81B 17.29% 8.13B 17.29% 8.13B
-Accounts receivable
9.18% 6.36B 13.05% 6.32B 13.57% 6.67B 13.57% 6.67B
-Other receivables
21.85% 1.31B 39.16% 1.48B 38.03% 1.45B 38.03% 1.45B
Inventory
1.95% 3.9B 6.34% 3.89B -2.37% 3.89B -2.37% 3.89B
Prepaid assets
-14.86% 2.81B -16.58% 2.7B -11.87% 2.53B -11.87% 2.53B
Total current assets
-1.04% 17.12B 2.17% 16.96B 5.67% 18.45B 5.67% 18.45B
Non current assets
Net PPE
3.08% 9.13B 5.48% 9.1B 3.49% 8.99B 3.49% 8.99B
-Gross PPE
2.94% 19.25B 5.29% 19.24B 3.89% 18.96B 3.89% 18.96B
-Accumulated depreciation
-2.82% -10.12B -5.13% -10.14B -4.24% -9.98B -4.24% -9.98B
Goodwill and other intangible assets
-4.04% 11.39B -4.94% 11.37B 3.28% 11.58B 3.28% 11.58B
-Goodwill
0.2% 3.89B 0.38% 3.89B 3.33% 3.89B 3.33% 3.89B
-Other intangible assets
-6.11% 7.5B -7.49% 7.48B 3.25% 7.69B 3.25% 7.69B
Investments and advances
-25.55% 2.59B -15.63% 2.73B 8.29% 3.21B 8.29% 3.21B
Non current deferred assets
-11.33% 2.37B -6.98% 2.46B -12.05% 2.49B -12.05% 2.49B
Other non current assets
22.89% 4.47B 14.09% 4.29B 17.47% 4.08B 17.47% 4.08B
Total non current assets
-1.85% 29.95B -0.92% 29.95B 4.05% 30.35B 4.05% 30.35B
Total assets
-1.56% 47.06B 0.17% 46.92B 4.66% 48.81B 4.66% 48.81B
Liabilities
Current liabilities
Payables
-7.95% 2.67B -16.44% 2.03B -6.59% 2.68B -6.59% 2.68B
-accounts payable
3.85% 1.66B -12.58% 1.43B 3.98% 1.67B 3.98% 1.67B
-Total tax payable
-76.11% 126.6M -24.42% 598.3M -74.37% 126.9M -74.37% 126.9M
-Dividends payable
14.45% 882.2M -- 0 14.91% 885.5M 14.91% 885.5M
Current accrued expenses
13.58% 7.99B 16.27% 6.77B 16.96% 6.85B 16.96% 6.85B
Current debt and capital lease obligation
19.3% 2.12B 27571.43% 1.36B 17581.61% 1.54B 17581.61% 1.54B
-Current debt
19.3% 2.12B 27571.43% 1.36B 17581.61% 1.54B 17581.61% 1.54B
Other current liabilities
-23.67% 2B -9.62% 2.54B 10.08% 3.03B 10.08% 3.03B
Current liabilities
3.49% 15.62B 14.27% 13.39B 20.6% 15.05B 20.6% 15.05B
Non current liabilities
Long term debt and capital lease obligation
-0.3% 14.69B -6.46% 15.15B -7.48% 15.35B -7.48% 15.35B
-Long term debt
-0.3% 14.69B -6.46% 15.15B -7.48% 15.35B -7.48% 15.35B
Non current deferred liabilities
-53.56% 862.5M -41.56% 1.29B -17.44% 1.73B -17.44% 1.73B
Employee benefits
-51.8% 1.89B -51.12% 1.94B -52.28% 1.95B -52.28% 1.95B
Other non current liabilities
-1.04% 1.78B -1.35% 1.71B -3.7% 1.64B -3.7% 1.64B
Total non current liabilities
-12.55% 22.78B -14.11% 24.07B -13.16% 24.6B -13.16% 24.6B
Total liabilities
-6.66% 38.4B -5.74% 37.46B -2.83% 39.65B -2.83% 39.65B
Shareholders'equity
Share capital
-0.67% 594.1M -0.93% 594.1M -0.32% 596.3M -0.32% 596.3M
-common stock
-0.67% 594.1M -0.93% 594.1M -0.32% 596.3M -0.32% 596.3M
Retained earnings
0.3% 8.56B 2.05% 9.37B 14.41% 8.96B 14.41% 8.96B
Paid-in capital
1.15% 6.75B 1.17% 6.66B 0.81% 6.83B 0.81% 6.83B
Less: Treasury stock
-4.17% 50.5M -4.17% 50.5M -5.39% 52.7M -5.39% 52.7M
Gains losses not affecting retained earnings
31.8% -4.29B 33.93% -4.23B 33.15% -4.34B 33.15% -4.34B
Other equity interest
0% -3.01B 0% -3.01B 0% -3.01B 0% -3.01B
Total stockholders'equity
32.59% 8.54B 35.25% 9.33B 59.16% 8.98B 59.16% 8.98B
Noncontrolling interests
-47.74% 114.5M -34.6% 131.2M -4.36% 175.6M -4.36% 175.6M
Total equity
29.95% 8.66B 33.28% 9.46B 57.16% 9.15B 57.16% 9.15B
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
CEO: Mr. David A. Ricks
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...